...
首页> 外文期刊>Dalton transactions: An international journal of inorganic chemistry >Complex formation equilibria of Cu~(II) and Zn~(II) with triethylenetetramine and its mono- and di-acetyl metabolites
【24h】

Complex formation equilibria of Cu~(II) and Zn~(II) with triethylenetetramine and its mono- and di-acetyl metabolites

机译:Cu〜(II)和Zn〜(II)与三亚乙基四胺及其单,二乙酰代谢物的络合物形成平衡

获取原文
获取原文并翻译 | 示例

摘要

Triethylenetetramine (TETA) dihydrochloride, or trientine, is a therapeutic molecule that has long been used as a copper-chelating agent for the second-line treatment of patients with Wilson's disease. More recently, it has also been employed as an experimental therapeutic molecule in diabetes where it improves cardiac structure in patients with diabetic cardiomyopathy and left-ventricular hypertrophy. TETA is metabolized by acetylation, which leads to the formation of two main metabolites in humans and other mammals, monoacetyl-TETA (MAT) and diacetyl-TETA (DAT). These metabolites have been identified in the plasma and urine of healthy and diabetic subjects treated with TETA, and could themselves play a role in TETA-mediated copper chelation and restoration of physiological copper regulation in diabetes. In this regard, a potentiometric and spectrophotometric study of Cu~(II)-complex formation equilibria of TETA, MAT and DAT is presented here, to provide a comprehensive evaluation of the stoichiometries of the complexes formed and of their relative stability constants. A potentiometric study has also been conducted on the corresponding Zn~(II) complexes, to evaluate any possible interference with TETA-mediated Cu~(II) binding by this second physiological transition-metal ion, which is present in similar concentrations in human plasma and which also binds to TETA. An ESI-MS study of these systems has both confirmed the complex formation mechanisms established from the potentiometric and spectrophotometric results, and in addition provided direct information on the stoichiometry of the complexes formed in solution. These data when taken together show that the 1:1 complexes formed with Cu~(II) and Zn II have different degrees of protonation. The stability of the Cu~(II) and Zn~(II) complexes with the three ligands, evaluated by the parameters pCu and pZn, decreases with the introduction of the acetyl groups. Nevertheless the stability of Cu~(II) complexes with MAT is sufficiently high to enable its participation in copper scavenging from the patient. A speciation study of the behavior of TETA and MAT with Cu~(II) in the presence of Zn~(II) at peri-physiological plasma concentrations is also presented. While Zn~(II) did not hinder copper binding, the possibility is raised that prolonged TETA treatment could possibly alter the homeostatic regulation of this essential metal ion. The lack of reliable literature stability constants concerning the Cu~(II) and Zn II interaction with the major transport proteins in plasma is also briefly considered.
机译:三亚乙基四胺(TETA)二盐酸盐或曲恩汀是一种治疗分子,长期以来被用作铜螯合剂,用于威尔逊氏病患者的二线治疗。最近,它还被用作糖尿病的实验性治疗分子,它可以改善糖尿病性心肌病和左心室肥大患者的心脏结构。 TETA通过乙酰化作用进行代谢,从而导致人类和其他哺乳动物中两种主要代谢物单乙酰-TETA(MAT)和二乙酰-TETA(DAT)的形成。这些代谢物已经在接受TETA治疗的健康和糖尿病患者的血浆和尿液中鉴定出来,它们本身可能在TETA介导的铜螯合和糖尿病中生理铜调节的恢复中发挥作用。在这方面,这里介绍了TETA,MAT和DAT的Cu〜(II)-配合物形成平衡的电位和分光光度研究,以提供对形成的配合物的化学计量及其相对稳定常数的全面评估。还对相应的Zn〜(II)配合物进行了电位研究,以评估第二种生理过渡金属离子对TETA介导的Cu〜(II)结合的任何可能干扰,该离子在人体血浆中的浓度相似。并且也绑定到TETA。对这些系统的ESI-MS研究不仅证实了由电位法和分光光度法建立的络合物形成机理,而且还提供了有关溶液中形成的络合物化学计量的直接信息。这些数据加在一起表明,Cu〜(II)和Zn II形成的1:1配合物具有不同的质子化程度。通过参数pCu和pZn评估,具有三个配体的Cu〜(II)和Zn〜(II)配合物的稳定性随乙酰基的引入而降低。但是,Cu〜(II)与MAT配合物的稳定性足够高,可以使其参与从患者体内清除铜的活动。还提出了在血浆中生理浓度的Zn〜(II)存在下TETA和MAT与Cu〜(II)的行为的形态学研究。尽管Zn〜(II)不会阻碍铜的结合,但延长TETA处理可能会改变该基本金属离子的稳态调节的可能性增加了。还简要地考虑了缺乏可靠的关于Cu〜(II)和Zn II与血浆中主要转运蛋白相互作用的文献稳定常数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号